-
-
-
-
-
-
-
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress
-
-
-
-
-
-
-
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Rocket Pharmaceuticals receives FDA RMAT designation for heart gene therapy
-
-
-
-
-
-
-
Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy
-
-
-
-
-
-
-
Rocket Pharmaceuticals (RCKT) Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data
-
-
-
-
-
-
-
Rocket Pharmaceuticals (RCKT) Appoints Mikael Dolsten to its Board
-
-
-
-
-
-
-
Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy
-
1,158,058 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

